A commentary notes that although this study provides more context to the use of aspirin as a colorectal cancer (CRC) preventative agent, it provides no assessment of the potential harms of aspirin in these cohorts and does not assess the full range of aspirin’s benefits beyond its cancer-preventive effects. Moreover, aspirin’s long-term effects, if any, on cancer and overall mortality are not addressed. The commentators suggest that to reflect accurately the complex, real-world clinical scenarios in which physicians and patients contemplate the use of aspirin, any truly informative analysis of its use must weigh its cumulative benefits against its cumulative risks. They note that two ongoing RCTs of aspirin in older patients should provide important additional detail on all of these points. Until then, they conclude “learning that aspirin’s preventive effects on GI tract cancer seem to extend even to those individuals who undergo CRC screening provides further support for aspirin’s possible future use as a cancer-preventive agent.”